Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study.

Authors
Journal	Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 79 Issue 9 Pg. e121 (09 2020) ISSN: 1468-2060 [Electronic] England
PMID	32816784 (Publication Type: Journal Article, Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!